/C O R R E C T I O N -- Abbott Laboratories/ In the news release, Longest Study of Kaletra(R) (Lopinavir/Ritonavir) Based Regimen Demonstrated Favorable Resistance Profile for Patients Through Six Years of Initial HIV Therapy, issued earlier today by Abbott Laboratories over PR Newswire, the third paragraph, first sentence should read "Data from the randomized, uncontrolled, prospective Phase II study of 100 treatment- naive patients taking Kaletra..." rather than "...100 treatment-naove patients taking Kaletra..." as incorrectly transmitted by PR Newswire. PRNewswire -- Nov. 1 DATASOURCE: Abbott Laboratories Web site: http://www.abbott.com/ Company News On-Call: http://www.prnewswire.com/comp/110328.html

Copyright